U.S. Markets closed

Arena Pharmaceuticals, Inc. (ARNA)

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
Add to watchlist
14.88-1.31 (-8.09%)
At close: 4:00PM EDT
People also watch
  • It's like it closed at $1.488. Friday June 23, 2017. PPS collapsed Huuuge. Thing that's amazing is only 47% of trades shorted ARNA.
  • 7,172,696 shares given to insiders on June 22. Bloated BOD. Top heavy with "leadership". Heavy with chief this and chief that and VP this and VP that. CEO 7mos compensation of $4.38M in 2016.Awarded 2,150,000 free shares on Feb14 2017. LOL
  • ARNA rated a Top 5 WORST Stock on Nasdaq in great SA June 19 research analysis
  • ZACKS 6/23/2017 recommends investors to remain firmly on the sidelines
  • Yesterday's announcement by partner Eisai who cut royalties on poor selling Belviq to arna confirms nothing, but that they'll proceed with required FDA testing. Eisai P.R.: WOODCLIFF LAKE, N.J., June 21, 2017 /PRNewswire/ -- Eisai Inc. today announced that the ongoing investigational CAMELLIA-TIMI 61 study of lorcaserin (marketed as BELVIQ® CIV) will continue as planned, based on the recommendation of an independent Data Monitoring Committee (DMC) after it completed a pre-specified interim safety analysis evaluating the incidence of MACE events, defined as cardiovascular death, myocardial infarction or stroke. The DMC will continue to monitor the ongoing safety of lorcaserin as planned.

    The five-year study, comprised of 12,000 patients, is being conducted in partnership with the Thrombolysis in Myocardial Infarction (TIMI) Study Group and is intended to address the post-marketing requirement from the U.S. Food and Drug Administration to evaluate the long-term cardiovascular safety of lorcaserin.

    The study is expected to conclude in 2018.
  • Yes, Belviq is the poorest revenue producer of all obesity agents. Yes, Belviq is a distant 3rd behind #1 Contrave and #2 Qsymia even though belflop was 1st approved Yes, completion of FDA required post approval study will do nothing. Yes arna had a 92% decline in Bel sales rev 1Q17 compared to 4thQ16. Yes, the terrible Bel revenue stream can't fund Arna's old pipeline for saturated markets. Yes, the 1:10 RS doesn't change what garbage this stock is
  • Paid pumpers and Desperate Underwater Longtards hoping the naive don't realize a 1:10 Reverse Split happened. Longs failed investors. Over 100 Million long shares failed to vote at ASM. Didn't know how to vote their shares held by brokerages like scotttrade etc.
  • LOL 7,172,696 shares given to insiders on June 22 Proposed maximum aggregate offering price $95,325,129.84 Amount of
    registration fee $11,048.18
  • Here it goes circling down the toilet bowl after RS. Shorts are going to destroy this T#urd and that's before the coming dilution.
  • Awww....$1.48 The whopper flippers thrilled to see this whopping pps. Their whopper shares reduced by 90% and their Big Whopper Beldud had royalties reduced 69.8%.

  • AWW....$1.52. The whopper flippers got served up by the cow milkers yesterday..They love the management team that takes takes takes....whopper flippers gave them 7M more shares....apple or cherry pipe with that....
  • Since RSS has stopped trading on Frankfurt Germany Exchange. Very Bad Indeed
  • Longtards overjoyed that Eisai didn't share Interim Results from FDA ordered post approval study only that they'll continue the mandated study. Bel sales expected to fall another 41% in 2Q. Revenues from ARNA only drug can't fund pipeline.
  • It's like it closed at $1.61. Last time in 16's/$1.60's was March. LOL. Down on huuuuge volume! Good news is just 25.4% of trades went short.
  • $14.88 means $1.488
  • Junk Stock before Reverse Split. Junk Stock after Reverse Split.
  • Huge Dilution.......Soon !!
  • Belviq will always be marginally effective at weightloss and will always be a poor seller.
  • dilution is a problem . BUY if you want too be deluted . their is big issue with there profuct.

    this syock eill see 2.00 dollats by December .
  • Arnatards are still desperate and underwater they just have 90% less shares